|
1
|
Singh D, Agusti A, Anzueto A, Barnes PJ,
Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, et al:
Global strategy for the diagnosis, management, and prevention of
chronic obstructive lung disease: The GOLD science committee report
2019. Eur Respir J. 53(100164)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Al Wachami N, Guennouni M, Iderdar Y,
Boumendil K, Arraji M, Mourajid Y, Bouchachi FZ, Barkaoui M,
Louerdi ML, Hilali A and Chahboune M: Estimating the global
prevalence of chronic obstructive pulmonary disease (COPD): A
systematic review and meta-analysis. BMC Public Health.
24(297)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Global Initiative for Asthma (GINA):
Global Strategy for Asthma Management and Prevention; GINA,
Fontana, WI, 2024. https://ginasthma.org/. Accessed January 10, 2025.
|
|
4
|
World Health Organization (WHO): Asthma.
WHO, Geneva, 2023. https://www.who.int/news-room/fact-sheets/detail/asthma.
Accessed September 8, 2025.
|
|
5
|
Mart MF and Peebles RS Jr: Asthma-chronic
obstructive pulmonary disease overlap syndrome. Curr Opin Immunol.
66:161–166. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Barnes PJ: New therapies for asthma: Is
there any progress? Trends Pharmacol Sci. 31:335–343.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aprile S, Colombo G, Serafini M, di Paola
R, Pisati F, Bhela IP, Cuzzocrea S, Grosa G and Pirali T: An
unexpected deuterium-induced metabolic switch in doxofylline. ACS
Med Chem Lett. 13:1278–1285. 2022.
|
|
8
|
Page CP: Doxofylline: A ‘novofylline’.
Pulm Pharmacol Ther. 23:231–234. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cazzola M, Page CP, Calzetta L, Rogliani P
and Matera MG: Doxofylline: Advancing and empowering equitable
asthma and COPD management beyond tradition. Adv Therap.
7(2400103)2024.
|
|
10
|
Matera MG, Page C and Cazzola M:
Doxofylline is not just another theophylline! Int J Chron Obstruct
Pulmon. Dis. 12:3487–3493. 2017.
|
|
11
|
van Mastbergen J, Jolas T, Allegra L and
Page CP: The mechanism of action of doxofylline is unrelated to
HDAC inhibition, PDE inhibition or adenosine receptor antagonism.
Pulm Pharmacol Ther. 25:55–61. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Singh N, Shreshtha AK, Thakur MS and Patra
S: Xanthine scaffold: Scope and potential in drug development.
Heliyon. 4(e00829)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rogliani P, Calzetta L, Ora J, Cazzola M
and Matera MG: Efficacy and safety profile of doxofylline compared
to theophylline in asthma: A meta-analysis. Multidiscip Respir Med.
14(25)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bender AT and Beavo JA: Cyclic nucleotide
phosphodiesterases: Molecular regulation to clinical use. Pharmacol
Rev. 58:488–520. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Surapisitchat J, Jeon KI, Yan C and Beavo
JA: Differential regulation of endothelial cell permeability by
cGMP via phosphodiesterases 2 and 3. Circ Res. 101:811–818.
2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Billington CK, Ojo OO, Penn RB and Ito S:
cAMP regulation of airway smooth muscle function. Pulm Pharmacol
Ther. 26:112–120. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shukla D, Chakraborty S, Singh S and
Mishra B: Doxofylline: A promising methylxanthine derivative for
the treatment of asthma and chronic obstructive pulmonary disease.
Expert Opin Pharmacother. 10:2343–2356. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cazzola M, Calzetta L, Barnes PJ, Criner
GJ, Martinez FJ, Papi A and Gabriella Matera M: Efficacy and safety
profile of xanthines in COPD: A network meta-analysis. Eur Respir
Rev. 27(180010)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Billington CK, Penn RB and Hall IP: β2
agonists. Handb Exp Pharmacol. 237:23–40. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Georgakopoulou VE, Gkoufa A, Garmpis N,
Garmpi A and Damaskos C: Inhaled bronchodilators and
corticosteroids in the management of bronchiolitis obliterans due
to allogenic hematopoietic stem cell transplantation. Oman Med J.
37(e388)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Stolz D, Matera MG, Rogliani P, van den
Berge M, Papakonstantinou E, Gosens R, Singh D, Hanania N, Cazzola
M, Maitland-van der Zee AH, et al: Current and future developments
in the pharmacology of asthma and COPD: ERS seminar, Naples 2022.
Breathe (Sheff). 19(220267)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Garmpi A, Damaskos C, Garmpis N,
Kaminiotis VV, Georgakopoulou VE, Spandidos DA, Papalexis P,
Diamantis E, Patsouras A, Kyriakos G, et al: Role of histone
deacetylase inhibitors in diabetic cardiomyopathy in experimental
models (Review). Med Int (Lond). 2(26)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zwinderman MRH, de Weerd S and Dekker FJ:
Targeting HDAC complexes in asthma and COPD. Epigenomes.
3(19)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Riffo-Vasquez Y, Man F and Page CP:
Doxofylline, a novofylline inhibits lung inflammation induced by
lipopolysacharide in the mouse. Pulm Pharmacol Ther. 27:170–178.
2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Leppänen T, Tuominen RK and Moilanen E:
Protein kinase C and its inhibitors in the regulation of
inflammation: Inducible nitric oxide synthase as an example. Basic
Clin Pharmacol Toxicol. 114:37–43. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jiao P, Li W, Shen L, Li Y, Yu L and Liu
Z: The protective effect of doxofylline against lipopolysaccharides
(LPS)-induced activation of NLRP3 inflammasome is mediated by SIRT1
in human pulmonary bronchial epithelial cells. Artif Cells Nanomed
Biotechnol. 48:687–694. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Riffo-Vasquez Y, Venkatasamy R and Page
CP: Steroid sparing effects of doxofylline. Pulm Pharmacol Ther.
48:1–4. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang Y, Zeng K, Wang J, Gao H, Nan Y and
Zheng X: Identifying the antiasthmatic target of doxofylline using
immobilized β2 -adrenoceptor based high-performance affinity
chromatography and site-directed molecular docking. J Mol Recognit.
29:492–498. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Calzetta L, Hanania NA, Dini FL, Goldstein
MF, Fairweather WR, Howard WW and Cazzola M: Impact of doxofylline
compared to theophylline in asthma: A pooled analysis of functional
and clinical outcomes from two multicentre, double-blind,
randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol
Ther. 53:20–26. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
DrugBank: Doxofylline (Internet).
https://go.drugbank.com/drugs/DB09273. Accessed
September 8, 2025.
|
|
31
|
DrugBank: Theophylline (Internet).
https://go.drugbank.com/drugs/DB00277. Accessed
September 8, 2025.
|
|
32
|
GBD 2019 Chronic Respiratory Disease
Collaborators. Global, regional, and national deaths, prevalence,
disability-adjusted life years, and years lived with disability for
chronic respiratory diseases, 1990-2019: A systematic analysis for
the Global Burden of Disease Study 2019. Lancet Respir Med.
8:585–596. 2020.
|
|
33
|
Global Initiative for Chronic Obstructive
Lung Disease (GOLD): Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease, 2025
report. GOLD, Fontana, WI, 2025. https://goldcopd.org.
|
|
34
|
Akram MF, Nasiruddin M, Ahmad Z and Ali
Khan R: Doxofylline and theophylline: A comparative clinical study.
J Clin Diagn Res. 6:1681–1684. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cazzola M, Calzetta L, Rogliani P, Page C
and Matera MG: Impact of doxofylline in COPD: A pairwise
meta-analysis. Pulm Pharmacol Ther. 51:1–9. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cazzola M and Matera MG: The effect of
doxofylline in asthma and COPD. Respir Med.
164(105904)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Khandelwal PN, Maaz SH and Borade DM:
Evaluation of efficacy and safety of doxofylline 800mg sustained
release tablet in treatment of patients with COPD: An open label,
prospective and RCT. Int J Basic Clin Pharmacol. 7:644–649.
2018.
|
|
38
|
Corlateanu A, Botnaru V, Covantev S,
Dumitru S and Siafakas N: Predicting health-related quality of life
in patients with chronic obstructive pulmonary disease: The impact
of age. Respiration. 92:229–234. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Safka KA, Wald J, Wang H, McIvor L and
McIvor A: GOLD stage and treatment in COPD: A 500 patient point
prevalence study. Chronic Obstr Pulm Dis. 4:45–55. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kraemer R, Smith HJ, Gardin F, Barandun J,
Minder S, Kern L and Brutsche MH: Bronchodilator response in
patients with COPD, Asthma-COPD-Overlap (ACO) and asthma, evaluated
by plethysmographic and spirometric z-score target parameters. Int
J Chron Obstruct Pulmon Dis. 16:2487–2500. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Calzetta L, Matera MG, Goldstein MF,
Fairweather WR, Howard WW, Cazzola M and Rogliani P: A long-term
clinical trial on the efficacy and safety profile of doxofylline in
Asthma: the LESDA study. Pulm Pharmacol Ther.
60(101883)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Poggi R, Brandolese R, Bernasconi M,
Manzin E and Rossi A: Doxofylline and respiratory mechanics.
Short-term effects in mechanically ventilated patients with airflow
obstruction and respiratory failure. Chest. 96:772–778.
1989.PubMed/NCBI View Article : Google Scholar
|
![Chemical structure of theophylline
and doxofylline
[7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione].
The presence of a dioxalane group at position 7 in doxofylline
differentiates it structurally from theophylline, contributing to
its improved safety and tolerability.](/article_images/br/23/5/br-23-05-02060-g00.jpg)
